London, United Kingdom

Paul Goldsmith

USPTO Granted Patents = 3 

Average Co-Inventor Count = 4.3

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Paul Goldsmith

Introduction

Paul Goldsmith is a notable inventor based in London, GB. He has made significant contributions to the field of medicine, particularly in the development of dosing methods for various drugs. With a total of three patents to his name, Goldsmith's work is focused on improving patient care through innovative drug administration techniques.

Latest Patents

Goldsmith's latest patents include a method for administering a dosage of Cagrisema for the treatment of obesity. This method involves receiving patient data, including weight data, and using a dosage calculator derived from a pharmacokinetic model to determine the appropriate dosage for the patient. Another significant patent is related to Apixaban dosing, which outlines a method for administering Apixaban to prevent or treat thrombosis. This method also relies on patient data, specifically a kidney function metric, to calculate the correct dosage using a plasma level prediction model.

Career Highlights

Goldsmith is currently associated with Closed Loop Medicine Ltd., where he continues to innovate in the field of drug administration. His work is characterized by a strong emphasis on personalized medicine, ensuring that treatments are tailored to individual patient needs.

Collaborations

Some of Goldsmith's notable coworkers include Michael Catt and Bruce Campbell. Their collaborative efforts contribute to the advancement of medical technologies and improve patient outcomes.

Conclusion

Paul Goldsmith's innovative patents and dedication to personalized medicine highlight his significant role in the medical field. His contributions are paving the way for more effective treatments and improved patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…